1.08
+0.03(+2.86%)
Currency In USD
| Previous Close | 1.05 |
| Open | 1.06 |
| Day High | 1.08 |
| Day Low | 1.03 |
| 52-Week High | 9.79 |
| 52-Week Low | 0.97 |
| Volume | 207,315 |
| Average Volume | 2.99M |
| Market Cap | 11.63M |
| PE | -0.5 |
| EPS | -2.15 |
| Moving Average 50 Days | 1.47 |
| Moving Average 200 Days | 1.94 |
| Change | 0.03 |
If you invested $1000 in Phio Pharmaceuticals Corp. (PHIO) 10 years ago, it would be worth $0 as of December 29, 2025 at a share price of $1.08. Whereas If you bought $1000 worth of Phio Pharmaceuticals Corp. (PHIO) shares 5 years ago, it would be worth $3.82 as of December 29, 2025 at a share price of $1.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
Newsfile
Dec 23, 2025 1:45 PM GMT
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical comp
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
Newsfile
Nov 25, 2025 4:30 PM GMT
King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to el
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress
Newsfile
Nov 17, 2025 1:45 PM GMT
Presenting INTASYL siRNA Drug TechnologyKing of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary